The observation that VEGF-D is associated with lymphatic disease rather than lung function decline or other aspects of disease activity or phenotype is consistent with a recent clinical trial where VEGF-D in patients with LAM was suppressed by inhibition of the mTOR pathway but did not parallel changes in lung function [15]. The gene discussed is VEGFD; the disease is lymphangioleiomyomatosis.